Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19) (Nano-COVID19)

This is an interventional treatment trial for Coronavirus focused on measuring coronavirus, inflammation, nanoparticles, methotrexate, covid19 Read More

Inclusion Criteria:

• Patients who were hospitalized with confirmed COVID-19
• Mild Coronavirus-19 disease (WHO Coronavirus-19 scale < 5)
• Fewer than 14 days since symptom onset.
• Female patient is not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile.
• Female patient is of childbearing potential must has a negative pregnancy test.
• Signing the study informed consent.

Exclusion Criteria:

• Need for oxygen supplementation >4 L/min via nasal cannula or ≥40% via Venturi mask.
• Need for oxygen supplementation via high-flow nasal cannula.
• Need for invasive mechanical ventilation.
• Extent of pulmonary involvement > 50% by CT scan.
• Chronic renal failure (estimated glomerular filtration rate <30 mL/min/1.73 m2)
• History of liver cirrhosis (Bilirubins levels > 3mg/dl)
• History of heart failure ( Ejection fraction <40%)
• History of Steven-Johnson disease
• History of stroke in the last 6 months
• History of sickle cell disease
• Chronic use of oral steroid therapy or other immunosuppressive or biologic response modifiers.
• Prior history of chronic hepatitis B or C infection and known HIV positive.
• Patient undergoing chemotherapy for cancer
• Sepsis caused by fungal or multidrug resistant gram-negative bacteria
• Known allergy to methotrexate.
• Body mass index(BMI) > 40 or <18.5
• Pregnancy or breastfeeding.
• Patients enrolled in other clinical trials in the last 12 months
• Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.